UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2015-06, Vol.41 (12), p.1303-1304

2015

Volltextzugriff (PDF)

CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22

The Journal of experimental medicine, 2014-07, Vol.211 (8), p.1571-1583

2014

Volltextzugriff (PDF)

DOP35 Spatial transcriptomics reveals cellular niches associated with histological inflammation in postoperative Crohn’s Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i135-i136

2024

Volltextzugriff (PDF)

DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S113-S115

2021

Volltextzugriff (PDF)

DOP86 Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S117-S118

2021

Volltextzugriff (PDF)

P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S488-S489

2021

Volltextzugriff (PDF)

DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S108-S110

2020

Volltextzugriff (PDF)

P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S401-S402

2020

Volltextzugriff (PDF)

Prematurity among insulin-requiring diabetic gravid women

American journal of obstetrics and gynecology, 1989-07, Vol.161 (1), p.106-111

1989

Volltextzugriff (PDF)

Management of isoimmunized pregnancy by use of intravascular techniques

American journal of obstetrics and gynecology, 1988-10, Vol.159 (4), p.932-937

1988

Volltextzugriff (PDF)

Esophageal motility and symptoms after endoscopic injection sclerotherapy

Digestive diseases and sciences, 1985, Vol.30 (1), p.29-32

1985

Volltextzugriff (PDF)

Bacteremia after endoscopic injection sclerosis

Gastrointestinal endoscopy, 1983-08, Vol.29 (3), p.198-200

1983

Volltextzugriff (PDF)

Irritable‐inflammatory bowel disease: Recognizing a new overlap syndrome and an enigma wrapped inside a puzzle

Inflammatory bowel diseases, 2002-09, Vol.8 (5), p.373-374

2002

Volltextzugriff (PDF)

Pseudodiverticula secondary to injection sclerotherapy

Journal of clinical gastroenterology, 1983-10, Vol.5 (5), p.401-404

1983

Volltextzugriff (PDF)

Evolutioninthe Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease - Order Slowly Rises from the Chaos

Current Pharmacogenomics, 2006-12, Vol.4 (4), p.301-306

2006

Volltextzugriff (PDF)

Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complication

Gastroenterology (New York, N.Y. 1943), 2000-04, Vol.118 (4), p.A569-A569

2000

Volltextzugriff (PDF)

Defective gp180 expression in the buccal mucosa of patients with ulcerative colitis but not with Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1998-04, Vol.114, p.A1101-A1101

1998

Volltextzugriff (PDF)

Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease

PloS one, 2012-07, Vol.7 (7), p.e41594-e41594

2012

Volltextzugriff (PDF)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Journal of Crohn's and colitis, 2022-08, Vol.16 (8), p.1222-1234

2022

Volltextzugriff (PDF)

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

Alimentary pharmacology & therapeutics, 2020-12, Vol.52 (11-12), p.1658-1675

2020

Volltextzugriff (PDF)

Adherent-invasive E. coli metabolism of propanediol in Crohn’s disease regulates phagocytes to drive intestinal inflammation

Cell host & microbe, 2021-04, Vol.29 (4), p.607-619.e8

2021

Volltextzugriff (PDF)

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2020-10, Vol.159 (4), p.1541-1544.e2

2020

Volltextzugriff (PDF)

Prematurity among insulin-requiring diabetic gravid women

International journal of gynecology and obstetrics, 1990-02, Vol.31 (2), p.199-199

1990

Volltextzugriff (PDF)

Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis

Immunity (Cambridge, Mass.), 2018-12, Vol.49 (6), p.1077-1089.e5

2018

Volltextzugriff (PDF)

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

Neurology, 2011-04, Vol.76 (17), p.1500-1507

2011

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(98)

Publikationsform

Sprache

Englisch
(118)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease

CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22

DOP35 Spatial transcriptomics reveals cellular niches associated with histological inflammation in postoperative Crohn’s Disease

DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

DOP86 Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension

P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension

DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study

P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study

Prematurity among insulin-requiring diabetic gravid women

Management of isoimmunized pregnancy by use of intravascular techniques

Esophageal motility and symptoms after endoscopic injection sclerotherapy

Bacteremia after endoscopic injection sclerosis

Irritable‐inflammatory bowel disease: Recognizing a new overlap syndrome and an enigma wrapped inside a puzzle

Pseudodiverticula secondary to injection sclerotherapy

Evolutioninthe Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease - Order Slowly Rises from the Chaos

Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complication

Defective gp180 expression in the buccal mucosa of patients with ulcerative colitis but not with Crohn's disease

Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

Adherent-invasive E. coli metabolism of propanediol in Crohn’s disease regulates phagocytes to drive intestinal inflammation

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Prematurity among insulin-requiring diabetic gravid women

Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

Suchergebnisse filtern